MONOLISA™ Anti-HAV EIA detects total (IgG and IgM) antibodies to hepatitis A virus (HAV) in human (adult or pediatric) serum or plasma. Tests for total anti-HAV antibodies do not discriminate among different antibody classes. The presence of total anti-HAV is a sign of exposure to HAV. It does not distinguish between present and past infection and is therefore useful primarily for epidemiological purposes. The recent availability of anti-HAV vaccines has prompted the development of more sensitive assays, used for screening non-vaccinated individuals, to follow up on antibody response after vaccination, and to estimate the need and timing of booster vaccinations. Specificity in hepatitis testing is critical—trust Bio-Rad’s expertise in immunology and continually updated reagents for all hepatitis testing needs.